Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chlorambucil + rituximab + lenalidomide first-line therapy in elderly or frail patients with CLL
NL-OMON23278Phase 2Not yet recruiting
- Sponsor
- HOVON
- Start
- Sep 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of chlorambucil, rituximab and lenalidomide in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by HOVON. Primary endpoints: Dose-limiting toxicity, Maximum tolerated dose and 2 more. Planned start Sep 2011; status: not yet recruiting.
02
Drugs
chlorambucilrituximablenalidomide
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on NL-OMON23278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON23278.